AVDL (Avadel Pharmaceuticals) Change In Receivables : $-22.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Avadel Pharmaceuticals Change In Receivables?

Avadel Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2024 was $3.0 Mil. It means Avadel Pharmaceuticals's Accounts Receivable declined by $3.0 Mil from Sep. 2024 to Dec. 2024 .

Avadel Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2024 was $-22.0 Mil. It means Avadel Pharmaceuticals's Accounts Receivable increased by $22.0 Mil from Dec. 2023 to Dec. 2024 .

Avadel Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2024 was $34.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Avadel Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2024 was 61.72.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Avadel Pharmaceuticals's liquidation value for the three months ended in Dec. 2024 was $19.1 Mil.

Avadel Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Avadel Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Change In Receivables Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

10.49

2.80

-12.10

-21.99

Avadel Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-5.86	-10.61	-10.22	-4.18	3.01

Avadel Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.0 Mil.

Avadel Pharmaceuticals (NAS:AVDL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Avadel Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	34.097	/	50.41	*	91
=	61.72

2. In Ben Graham's calculation of liquidation value, Avadel Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Avadel Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	73.777	-	90.388	+	0.75 * 34.097	+	0.5 * 20.298
=	19.1

Avadel Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (NAS:AVDL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Executives

Linda Palczuk	director	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Peter Thornton	director	TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P
Thomas S Mchugh	officer: Chief Financial Officer	2280 SCHUETZ ROAD, ST. LOUIS MO 63146
Geoffrey Michael Glass	director	4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Greg J Divis	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Richard J Kim	officer: Chief Commercial Officer	16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550
Douglas J Williamson	officer: Chief Medical Officer	AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Sandra L Hatten	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jason Vaughn	officer: Sr. VP, Technical Operations	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jordan Dubow	officer: Chief Medical Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael F Kanan	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
David P Gusky	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael S Anderson	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15